A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma
Authors
Keywords
-
Journal
Canadian Journal of Gastroenterology and Hepatology
Volume 2018, Issue -, Pages 1-10
Publisher
Hindawi Limited
Online
2018-02-13
DOI
10.1155/2018/1863535
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hypermutation In Pancreatic Cancer
- (2017) Jeremy L. Humphris et al. GASTROENTEROLOGY
- Promoter hypermethylation in plasma-derived cell-free DNA as a prognostic marker for pancreatic adenocarcinoma staging
- (2017) Stine Dam Henriksen et al. INTERNATIONAL JOURNAL OF CANCER
- Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Margaret A. Tempero et al. Journal of the National Comprehensive Cancer Network
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Para-aortic node involvement is not an independent predictor of survival after resection for pancreatic cancer
- (2017) Cosimo Sperti et al. WORLD JOURNAL OF GASTROENTEROLOGY
- BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population
- (2017) Ying Zhu et al. Oncotarget
- More deaths from pancreatic cancer than breast cancer in the EU by 2017
- (2016) J. Ferlay et al. ACTA ONCOLOGICA
- The prognostic impact of para-aortic lymph node metastasis in pancreatic cancer: A systematic review and meta-analysis
- (2016) S. Paiella et al. EJSO
- Change in Pattern ofHER2Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines
- (2016) Mithun Vinod Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma
- (2016) Hyung Soon Park et al. Cancer Research and Treatment
- Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma
- (2016) Stine Dam Henriksen et al. Clinical Epigenetics
- SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
- (2015) M. Hidalgo et al. CLINICAL CANCER RESEARCH
- Biomarker: Predictive or Prognostic?
- (2015) Karla V. Ballman JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Postoperative Carcinoembryonic Antigen as a Complementary Tumor Marker of Carbohydrate Antigen 19-9 in Pancreatic Ductal Adenocarcinoma
- (2015) Jaihwan Kim et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA Hypermethylation as a Blood-Based Marker for Pancreatic Cancer
- (2015) Stine Dam Henriksen et al. PANCREAS
- Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies
- (2015) Andrea Teague et al. Therapeutic Advances in Medical Oncology
- Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
- (2014) J. L. Lindner et al. ANNALS OF ONCOLOGY
- Revisiting the Concept of Lymph Node Metastases of Pancreatic Head Cancer: Number of Metastatic Lymph Nodes and Lymph Node Ratio According to N Stage
- (2014) Mee Joo Kang et al. ANNALS OF SURGICAL ONCOLOGY
- Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
- (2014) T Golan et al. BRITISH JOURNAL OF CANCER
- The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer
- (2013) Beatrice Mohelnikova-Duchonova et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates
- (2013) K. E. Poruk et al. CURRENT MOLECULAR MEDICINE
- Provincial rates and time trends in pancreatic cancer outcomes
- (2013) S. Fung et al. Current Oncology
- Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
- (2013) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pancreatic Ductal Adenocarcinoma
- (2012) Ioannis T. Konstantinidis et al. ANNALS OF SURGERY
- CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy
- (2012) Werner Hartwig et al. ANNALS OF SURGICAL ONCOLOGY
- Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma
- (2012) Raphaël Maréchal et al. GASTROENTEROLOGY
- Cancer biomarkers
- (2012) N. Lynn Henry et al. Molecular Oncology
- Irrelevance of Microsatellite Instability in the Epidemiology of Sporadic Pancreatic Ductal Adenocarcinoma
- (2012) Luigi Laghi et al. PLoS One
- Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection
- (2012) Naoya Nakagawa et al. SURGERY
- Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy
- (2011) Amir Sonnenblick et al. CANCER BIOLOGY & THERAPY
- Serum Biomarker Panels for the Detection of Pancreatic Cancer
- (2011) R. E. Brand et al. CLINICAL CANCER RESEARCH
- Overcoming drug resistance in pancreatic cancer
- (2011) Jiang Long et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
- (2011) F. A. Sinicrope et al. JNCI-Journal of the National Cancer Institute
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions
- (2011) M. A. Lowery et al. ONCOLOGIST
- Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study
- (2010) Giuseppe Colucci et al. JOURNAL OF CLINICAL ONCOLOGY
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- A phase 2 clinical trial ofnab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma
- (2009) Evan M. Hersh et al. CANCER
- Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma
- (2009) R. Marechal et al. CLINICAL CANCER RESEARCH
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
- (2009) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
- (2009) David Cunningham et al. JOURNAL OF CLINICAL ONCOLOGY
- Margin Clearance and Outcome in Resected Pancreatic Cancer
- (2009) David K. Chang et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma
- (2008) Shishir K. Maithel et al. ANNALS OF SURGICAL ONCOLOGY
- Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
- (2008) James J. Farrell et al. GASTROENTEROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started